SCTX Scribe Therapeutics Inc.
Fundamentals / CIK 0001853921 / USDScribe Therapeutics Inc. reported $187.9M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open SCTX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$174.2M Total debt: $5.14M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $1.64M | $1.92M | -- | $20.11M | $4.90M | -- |
| Research & Development | $8.26M | $8.82M | -- | $14.42M | $13.88M | -- |
| Total Operating Expenses | $12.50M | $11.31M | -- | $17.95M | $16.52M | -- |
| Operating Income | -$10.86M | -$9.39M | -- | $2.16M | -$11.63M | -- |
| EBITDA | -$10.26M | -$8.79M | -- | $2.86M | -$10.93M | -- |
| Interest Expense | $0 | $276K | -- | $598K | $598K | -- |
| Income Before Tax | -$9.63M | -$6.26M | -- | $1.80M | -$10.62M | -- |
| Income Tax Expense | $231K | $212K | -- | $324K | -$712K | -- |
| Net Income | -$9.86M | -$6.48M | -$17.35M | $1.47M | -$9.90M | -$3.42M |
| Basic EPS | -$0.68 | -$2.62 | -- | $0.00 | -$4.08 | -- |
| Diluted EPS | -$0.68 | -$2.62 | -- | $0.00 | -$4.08 | -- |
| Basic Shares Outstanding | 14.5M | 2.5M | -- | 2.4M | 2.4M | -- |
| Diluted Shares Outstanding | 14.5M | 2.5M | -- | 2.4M | 2.4M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2025-12-31 |
|---|---|---|---|
| Cash & Cash Equivalents | $172.1M | $35.59M | $12.80M |
| Short-Term Investments | $2.18M | $7.42M | $45.17M |
| Cash & Short-Term Investments | $174.2M | $43.00M | $58.00M |
| Total Current Assets | $178.9M | $45.10M | $66.93M |
| Property, Plant & Equipment, Net | $5.15M | $5.75M | $7.01M |
| Other Non-Current Assets | $586K | $3.61M | $538K |
| Total Non-Current Assets | $9.04M | $12.82M | $11.29M |
| Total Assets | $187.9M | $57.93M | $78.22M |
| Accounts Payable | $2.77M | $2.77M | $4.57M |
| Deferred Revenue (Current) | $25.42M | $27.48M | $21.09M |
| Total Current Liabilities | $37.93M | $78.70M | $69.06M |
| Deferred Revenue (Non-Current) | $12.95M | $11.70M | $19.94M |
| Other Non-Current Liabilities | $8.15M | $7.92M | $7.49M |
| Total Non-Current Liabilities | $24.83M | $23.72M | $32.23M |
| Total Liabilities | $62.76M | $102.4M | $101.3M |
| Total Debt (incl. Leases) | $5.14M | $5.47M | $6.09M |
| Common Stock | $36K | $14K | $14K |
| Retained Earnings | -$191.4M | -$181.5M | -$157.7M |
| Accumulated Other Comp. Income | $0 | -$2.0K | $35K |
| Total Stockholders' Equity | $125.2M | -$164.8M | -$143.4M |
| Total Equity | $125.2M | -$164.8M | -$143.4M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$9.86M | -$6.48M | -$17.35M | $1.47M | -$9.90M | -$3.42M |
| Depreciation & Amortization | $600K | $600K | -- | $700K | $700K | -- |
| Stock-Based Compensation | $1.22M | $227K | -- | $2.23M | $676K | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 4.72x | 0.57x | -- | -- | -- | -- |
| Quick Ratio | 4.59x | 0.55x | -- | -- | -- | -- |
| Debt to Equity | 0.04x | -- | -- | -- | -- | -- |
| Revenue Growth (YoY) | -91.9% | -60.8% | -- | -- | -- | -- |
| Operating Income Growth (YoY) | -602.6% | -- | -- | -- | -- | -- |
| Net Income Growth (YoY) | -770.0% | -- | -- | -- | -- | -- |